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DRUG USE AND POLICY: 
A CROSS-DISCIPLINE DIALOGUE
BY SHEVYA AWASTHI, MATTHEW COLBERT, DOYEL DAS, EMILY 
HARARI, CASSIDY HARDIN, ROSA LEE, MICHELLE LEE, ELETTRA 
PREOSTI, MELANIE RUSSO, AND SAUMI SHOKRAEE
DAVID SHOWALTER1: I’m a sixth-
year PhD student in Sociology here 
at UC Berkeley. I use qualitative and 
ethnographic methods to study 
drug use and drug policy. In particu-
lar, I focus on opioid use and injection 
drug use. I come from a background 
of harm reduction work—for the 
past ten years, I’ve been involved 
in syringe exchange and overdose 
prevention programs. An important 
underlying principle to my research 
is helping people who use drugs live 
healthier and happier lives.
DR. VERONICA MILLER2: I’m 
in the School of Public Health, 
and my perspective is on the 
regulation of new drug products. 
I teach a class on the Food and 
Drug Administration (FDA), drug 
development, and public health. 
My research program is con-
centrated in specific disease 
areas, in which we facilitate the 
drug development path.
DR. JOHANNES ‘HAN’ DE JONG4: 
I’m a postdoc in the Molecular and Cell 
Biology department. I study drugs as 
chemicals and how they affect the 
brain. Before that, I did my PhD in the 
Netherlands, where I studied sugar 
in the context of food addiction. I was 
also a member of a liberal political 
party called Democrats 66, which 
was the first party to legalize drugs in 
the Netherlands in the 1990s. I have 
also been involved in several harm re-
duction programs as a volunteer and 
an educator.
BREANNA FORD3: I am a
fifth-year graduate student in 
Endocrinology, and most of my 
research is about molecular tox-
icology. I primarily look at pesti-
cides and their harmful effects 
on humans. I also look at endog-
enous metabolites formed by 
pharmaceuticals and their di-
rect interactions with the body. 
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BSJ: What are the neurobiological mechanisms underlying ad-diction?
JDJ: The first phase in the development of addiction is calledsensitization. Drugs affect the dopamine system in your 
brain, which reinforces behaviors that make you feel good. For in-
stance, if you smoke cigarettes, you might not actually enjoy smok-
ing, but the nicotine stimulates your brain to reinforce the behavior. 
That leads to the second phase, which is the conditioning phase. If 
you are trying to quit smoking and you see cigarettes on the table, 
then they are a salient cue for you to start smoking again. Over time, 
the drugs hijack the reward systems in your brain—both the dopa-
mine system and the system that controls it break down. You cannot 
tell someone to stop being addicted—the very brain areas that they 
need to do that are destroyed.
BSJ: There is the historical example of veterans of the VietnamWar who used heroin while in Vietnam, but no longer 
sought it out when they got back to the United States. Could you 
elaborate on this phenomenon?
JDJ: This is a famous example, along with the example of RatPark, which was a series of studies in the 1970s on drug 
addiction in rats.5 The rats were exposed to a solution of morphine 
and would constantly drink it when in an isolated environment. 
However, when exposed to a more socially enriching environment, 
the rats would stop drinking the morphine. The same happened to 
heroin users who came back from Vietnam. Stressful environmental 
and social factors, combined with the effects of the chemical itself, 
caused the heroin addiction. After Vietnam, veterans came back to 
an environment where these social and psychological stressors no 
longer existed, so many people were suddenly not addicted anymore. 
However, there was a certain percentage of veterans who continued 
to be addicted to heroin despite having a family and being happy at 
home. We might conclude that these people were simply addicted 
to the chemical itself. Thus the biological, psychological, and social 
factors lead to addiction, but there’s an ongoing debate about which 
factors are more influential.
DS: These examples are extreme cases, since most people whotry heroin don’t become addicted to it. There’s a big gap 
between the number of people who have ever used heroin and the 
number of people who fit the criteria for heroin use disorder. There’s 
so much more about what leads people to destructively use drugs 
beyond simply consuming the chemical. It’s important to underline 
the difference between using a drug and being addicted to it.
VM: I wanted to ask a question from the perspective of some-one who studies the regulation of pain medicine. Sup-
pose someone breaks their leg while skiing. They get a prescription 
for pain relief medication, and two weeks later they become addicted 
to the medication. How do pain relief and addiction interact in the 
brain?
JDJ: The mu opioid receptor is the brain’s natural pain-regulat-ing system. That system is under tight control. Every pain 
medication that works on this system in some way down-regulates 
the mu opioid receptors. Over time, these interactions can change 
the system in a way that makes you addicted to the medication. 
Morphine has one of the strongest interactions with the mu opioid 
receptor. The trick is that morphine works in your body, but the 
blood-brain barrier prevents it from entering your brain. This makes 
morphine a good pain medication but not super addictive. On the 
other hand, heroin can sneak into the brain and become addictive. 
The holy grail of pain medication is to make a chemical that will only 
act in your body and not in your brain. 
DS : Pain, whether physical or psychological, is at the root ofwhy people use drugs. In a clinical setting, it’s definitely 
true that widespread availability of prescription opioids is what got 
a lot of people hooked on the pills. However, about three quarters of 
people who are dependent on prescription opioids will say they first 
got them not from a doctor, but from a friend who got them from a 
doctor. We can’t just cut people off from the pills, because the people 
who are prescribed the pills aren’t the ones who are having problems 
using them. Instead, we need to think about how to prevent strong 
medications from getting into the hands of people who aren’t able to 
use them in a safe way. The concern about addiction is sometimes 
misplaced when we just blame doctors or pharmaceutical compa-
nies.
BSJ: How does the FDA treat clinical and recreational drugsdifferently? Are there any instances of hypocrisy in the leg-
islation?
VM: The FDA regulates medicines. These types of drugs in-clude monoclonal antibodies, biologics, and vaccines; 
they all have a specific medicinal purpose. The drug packaging in-
sert tells you what the drug is supposed to be used for and how it 
is supposed to be used. The FDA also has a regulatory oversight. 
They regulate what drugs come into the country, and they can go to 
the border and inspect shipments. Today, the FDA’s efforts have ex-
panded into social networks, as they examine websites that sell illicit 
drugs. The FDA has three primary roles: the first is to make sure we 
Research on both recreational and pharmaceutical drugs spans fields from neuroscience to sociology. This multidis-
ciplinary approach informs regulatory drug policy and shapes the way drugs are perceived in society. The Berkeley 
Scientific Journal sat down with a diverse group of researchers (Fig. 1) to hear their insights into the mechanisms of 
drug addiction, challenges in drug regulation, and international attitudes toward drug rehabilitation.
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have safe medicines to treat pain. The second is to make sure we have 
medicines to counteract addiction. The third is to oversee the import 
of drugs. Ultimately, the FDA looks at benefit and risk: what is the 
benefit that the drug provides, and what is the risk that the drug pos-
es? The FDA cannot regulate clinical practice, because once a drug 
is approved, doctors have the discretion to prescribe drugs off-label, 
meaning in a way that is not indicated on the packaging insert. In a 
way, the FDA has its hands tied in directly interfering with the opioid 
epidemic besides encouraging the development of new drugs to treat 
addiction.
BF: I have a follow-up. The question addressed hypocrisy, butI’m not sure if hypocrisy is the most holistic term for what I 
think of as gaps in FDA oversight. To me, something that potentially 
falls into that category is that the FDA regulates food and pharma-
ceutical medications, but it doesn’t regulate supplements and natural 
products that don’t have a stated therapeutic value. Is it a problem 
that the FDA does not regulate these products?
VM: There are other agencies that regulate food, like theUSDA. But the minute a supplement is claimed to have a 
medical benefit, it becomes a drug, and then the FDA can bar it from 
being sold as a drug. So I think that whole area is a wide open field, 
and much more could be done by the FDA. 
BSJ: What obstacles posed by the FDA interfere with the pro-cess of drug research?
JDJ: A major issue is drug scheduling. In terms of addiction re-search, most addictive drugs are not Schedule I. I can easily 
do cocaine research because it’s a Schedule II drug. It’s the same for 
ketamine, a Schedule III drug that is frequently used for depression 
research. Meanwhile, marijuana is Schedule I, so nobody in the US 
can easily study it. For scientists, the bureaucratic process makes it 
difficult to conduct this research. MDMA, a methamphetamine, is 
another example. MDMA might have potential for treating PTSD, 
but it is very difficult to study because it is a Schedule I drug.
BF: Our lab does a lot of drug development research, and allof it is very pre-clinical—it will be years before our research 
interacts with the FDA. For most drug development research, the 
FDA does not have any direct interaction with researchers in the ac-
ademic environment unless they are studying items that are analogs 
of known Schedule I substances or are part of the synthesis pathways 
of these substances.
BSJ: Besides drugs, pesticides are other chemicals that can betaken up by the human body. How do pesticides affect hu-
man health?
BF: We have this general belief that things that are naturalmust be good. This is reasonable in many ways. We eat food, 
which grows from the ground, and therefore we think things that 
grow from the ground must be okay, whereas things that are syn-
thesized in a lab must be horrible for us. Pesticides are an example 
of this; we think of them as intentional, synthesized poisons, and 
therefore they must be bad. But if you think about pesticides as they 
relate to pharmaceuticals, there’s a huge amount of overlap. Antibi-
otics and antifungals are really just pesticides that we use for a very 
specific purpose. This is where some of the ethical and psychologi-
cal issues around what we think of as natural and unnatural come 
into play, and where the regulatory aspect becomes really important, 
because all of this is about managing risk and benefit. Is the risk of 
potential adverse effects of a pesticide, whether used in an agricul-
tural or pharmaceutical way, worth the benefits it affords us both as 
individuals and as a group?  
VM: Without getting too much into the endocrine system,most foreign things introduced to the body get metabo-
lized by the liver. If the liver’s enzymes have too much competition 
with these foreign elements, whether it’s aspirin, Tylenol, ibuprofen, 
or pesticides sprayed on your apple, this interferes with other liver 
functions and drug metabolisms. It’s all part of the same system.
BF: Exactly. The same can be said about the use of non-regulat-ed drugs. They’re all undergoing the same metabolism, and 
cross-interactions between illicit drugs and established pharmaceu-
ticals are going to occur in your body. Understanding these interac-
tions is incredibly important to maintaining human health.
Figure 1. Cross-discipline panel. From left to right: Researchers David Showalter, Breanna Ford, Dr. Han de Jong, and Dr. Veronica Miller sat down with 
a group of BSJ writers to share their insights on the role of drugs in modern society.
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Figure 1. Cross-discipline panel. From left to right: Researchers David Showalter, Breanna Ford, Dr. Han de Jong, and Dr. Veronica Miller sat down with 
a group of BSJ writers to share their insights on the role of drugs in modern society.
VM: A famous case of this is with St. John’s wort, [a flower-ing plant with possible antidepressant activity]. It plays 
around with those liver enzymes and can seriously diminish concen-
trations of metabolites that you actually need. This is why a doctor 
will always ask a patient to list all of the drugs they are taking, even if 
the drugs are over-the-counter.
BSJ: What are some shortcomings of our current attitudes to-wards addiction rehabilitation, especially when it comes to
illicit substances? 
JDJ: What is generally true in the US is that people arehigh-minded and have strong principles. Whereas in 
Dutch culture, we are not proud at all.
VM: The Dutch are very pragmatic.
JDJ: Exactly! When I tell people in the US that I am Dutch,they immediately think about parties in Amsterdam. We 
did not legalize marijuana because we are all hippies. We legalized 
marijuana because Dutch policymakers, who are literally the most 
boring people in the world, looked at the data and worked out the 
best way to approach the problem. In the Netherlands, a country of 
20 million people, there are 30 thousand heroin addicts. All of them 
are in treatment. The average age of the heroin addict increases by 
one year every year because the population is contained to the peo-
ple in treatment. Additionally, no market exists for a heroin dealer, 
since heroin addicts are able to get the drug from clinics for free and 
use them in a safe space with a clean needle. All it takes is for us to 
step away from our principles. It might feel wrong that a certain per-
centage of your income tax supports heroin addicts. After all, they 
do not work, they receive money from the state, they get a free place 
to live, and they are allowed to take drugs. But it is important to take 
a step back and think pragmatically about what the future is going 
to look like if we implement these policies. That is what happened in 
the Netherlands. I think this is perhaps the major flaw in US policy: 
policies are based in principles and not in facts.
VM: It is a science, whether social or medical, of what worksand what doesn’t.
DS: Another thing is the assumption that if you use drugs, youhave to go to treatment. Most people who quit using drugs 
don’t go to treatment to do it. Instead, most people quit using drugs 
by basically aging out of it. Drugs are predominantly used by young 
people, those who do not have other things going on in their lives, or 
those who are seeking relief from something in their lives. But peo-
ple grow up and get jobs, start families, fall in love, or find things that 
matter to them. These things fill the gaps that the drugs previously 
filled. As a result, these people no longer need drugs. There is also 
a lot of talk about the supply-side factor, such as overprescription. 
However, opioids were overprescribed in places that already had a 
large demand for drugs. These are usually places that have had sub-
stance abuse problems for decades. If we fix those root causes, there 
is going to be less of a demand for drugs. Therefore, I believe that 
the best treatment policy is ensuring that people have a good place 
to live, have a way to support themselves either through work or the 
welfare state, can form meaningful relationships, and aren’t separat-
ed from their children or family members. If we achieve these things, 
the downstream consequence is that there will be fewer reasons for 
people to turn to drugs in the first place.
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